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Cancer is a leading cause of mortality worldwide, the conventional chemotherapeutic drugs have been
known  for  their  toxicity  and  numerous  side  effects.  A  new  approach  to  treat  cancer  involves
phytochemical drugs. In the present review, anti-cancer activity of a class of steroidal lactones called
withanolides  obtained  from  Withania  somnifera (L.)  Dunal  is  discussed.  The  commonly  studied
bioactive compounds namely withaferin-A, withanoside IV, withanoside VI and withanolide-A among
others obtained from methanolic and chloroform extract of the leaves and various alcoholic, aqueous
and chloroform extract of roots have shown inhibition to various human cancer cell lines including skin,
breast,  colon,  prostate,  liver,  ovary,  cervical  and  lung.  Prominent  mechanisms  of  action  include
induction of apoptosis by NOS upregulation, ROS production and NBS2 or COX-2 inhibition; cytotoxicity
by humoral and cell mediated immune response, activation of p53 and pRB and inhibition of various
viral oncoproteins; cell cycle arrest by Cdc2 facilitated mitotic catastrophe, cyclin-D1 down-regulation
and inhibition of transcription factors. Cancers are also controlled by inhibition of angiogenesis and
metastasis  of the tumor cells.  In addition to anti-tumorogenic  properties,  W. somnifera also holds
properties that make it a potential adjuvant in integrated cancer therapeutics and in enhancing the
effectiveness of ongoing radiation therapy.
Introduction
One of the most common forms of medication involves
phytotherapy; plants show a vast molecular diversity
and  produce  numerous  therapeutic  phytochemicals.
Over  60%  of  the  people  across  the  world  rely  on
phytochemicals  to  cure  various  diseases.  Moreover,
currently,  extensive  studies  are  being  conducted  to
develop and screen new drugs in phytotherapy (1). It
is  essential  to  evaluate  and  screen  more  such
phytochemicals for pharmaceutical purposes (2). Most
of  these  phytotherapeutic  drugs  are  made  out  of
phytochemicals  mainly  comprising  lactones  and
alkaloids obtained from root,  stem, leaves and other
parts of a plant (3).
In fact, various herbal plants were reported to be
historically used as prophylactic agents for treatment
of cancer in India, Greece, China and Egypt (4). Indian
winter cherry is also known as Indian ginseng due to
resemblance in its usage with Chinese Panax ginseng.
It  is  more  commonly  referred  to  as  Ashwagandha
(meaning “horse-smell”) because the smell of its roots
resembles  that  of  a  horse  (5).  Its  scientific  name
Withania somnifera  (L.)  Dunal originates from Latin,
and it means “sleep-inducing” or sedative (3, 6).
The  taxonomic  position  of  W.  somnifera is  as
follows:
Kingdom – Plantae (Plants)
Subkingdom – Tracheobionta (Vascular plants)
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Super division   – Spermatophyta (Seed plants)
Division – Angiosperms
Class – Dicotyledoneae
Order – Solanales / Tubiflorae
Family – Solanaceae
Genus – Withania
Species – W. somnifera
W.  somnifera  is  described  as  a  small,  woody,
erect  and  evergreen  shrub  of  about  2  feet  tall
belonging to the Nightshade family. The roots of  W.
somnifera are whitish brown in color and stout fleshy
in appearance. Leaves are simple, with ovate margin
and glabrous surface; they are relatively smaller and
opposite  when  closer  to  the  flower.  The  flowers
borne by W. somnifera are small, inconspicuous and
greenish to lubrid yellow in color; the axillary flower
shows  umbellate  cyme  inflorescence.  Its  ripened
fruits are globose, orange red berries enclosed within
persistent  calyx  (Fig.  1)  and  shows  properties  to
coagulate  milk.  The  seeds  appear  yellow  and
reniform.
The origin of  W. somnifera can be traced back
in  the  Asian  countries  like  India,  Pakistan,
Afghanistan  and  other  dry  regions  like  South
Africa.  It  grows  in  Africa,  Mediterranean  region
and  India.  In  India,  it’s  found  to  grow  in  dry
regions  of  Manasa,  Neemuch,  Jhawad,  Hehsils  of
Mandsaur,  districts  of  Madhya  Pradesh,  Punjab,
Sindh and Rajasthan (6).
Pharmacological activity of W. somnifera
Various  steroidal  lactones obtained from root,  stem
and  leaves  of  W.  somnifera  show  therapeutic
properties that affect the immune system, circulatory
system,  CNS  etc  (7).  It  is  a  well-known  sedative,
hypnotic/narcotic and has the ability to boost energy.
Studies have shown that  W. somnifera  extracts have
positive  effects  on overall  health,  especially  during
pregnancy  and  increase  non-specific  resistance
against  various  physical,  chemical  and  biological
agents (8).  It has been used to treat arthritis, venom
toxins,  muscle  strain,  fatigue,  skin  infections,
rheumatoid  joint  inflammation,  aches  and
rheumatism (9).
It  has  been  prominently  used  as  anti-
ulcerogenic,  anti-diabetic,  anti-Parkinson’s,  anti-
fungal,  anti-malarial,  anti-hypertension,  anti-
inflammatory, anti-microbial, anti-stress, anti-ageing,
anti-fatigue,  analgesic,  immunomodulatory,
hepatoprotective,  free  radical  scavenging,
detoxifying, neurogenerative, chondroprotective and
cardio-protective  agent.  It  also  acts  as  an  anti-
depressant, anti-coagulant and anti-oxidant and is a
well-known rejuvenator (9).
Phytochemistry  and  bioactive  compounds
obtained from W. somnifera
Major  active  compounds  among  the  W.  somnifera
phytochemicals  are  over  20  alkaloids  including
anaferin,  cuscohygrine,  anahygrin  and  steroidal
lactones  such  as  withanolides,  withaferin,
withanamides,  withanosides  (Fig.  2),  withanolide
glycosides,  liganamides  and  steroidal  saponins  (10-
13).  Withanolides  are  a  family  of  structurally
complex  steroidal  lactones  which  act  as  potential
drugs and aid in various biological and physiological
activities  (14).  They  are  characterized  by  an
ergostane skeleton whose C-22 and C-26 are oxidized
to form δ lactones with 2-ene-1-one in ring A of the
steroid  (15).  They  are  given  the  name  22-Hydroxy
ergostane-26-oic  acid  26,22-d-lactone.  Steroidal
alkaloids  and  steroidal  lactones  (withanolides)  are
major constituents of alcohol extract of W. somnifera
(16).  Withanolide  biosynthesis  shows high  levels  of
tissue  specificity.  The  highest  abundance  of
withaferin-A is found to be in leaf tissue followed by
the bark, stem and roots. Conversely, withanolide-A
is  abundantly  biosynthesized  in  roots  followed  by
other tissues. Therefore in general both root and leaf
tissues  are  considered  to  study  the  biosynthesis  of
withanolides (16).
There are over 40 known withanolides of which
12 major  withanolides  obtained from  W. somnifera
are  withaferin  A,  sitoindosidic,  25-hydroxy-27-
desoxywithaferin-A,  2-3  dihydrowithaferin,
Physagulin-D,  PhysagulinD(1->6)-β-D-glucopyranosyl-
(1->4)-β-D-glcopyranoside,27-O-β-D-
glucopyranoylphysagulin  D,  withanoside  IV,  27-O-β-
D-glucopyranosylviscosalactone  B,  4,16-dihydroxy-
5β,6β-epoxyphysagulin  D,  viscosalactone  B,  and
diacetylwithaferin A.  Out of  these  the  most studied
are withaferin A, withanolide A and withanone (17).
Other  plants  reported  to  produce  withanolides
are  mostly  from  Solanaceae  and  rarely  from
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Fig. 1. Morphology of Withania somnifera (L.) Dunal during
fruiting stage.
Taccaceae,  Fabaceae  and  Lamiaceae.  Within
Solanaceae,  species  from  Withania genus  are  the
major producers, but 14 other reported withanolide
producing  genera  are  Acnistus,  Datura,  Deprea,
Dunalis,  Iochroma,  Jaborosa,  Lycium,  Nicandra,
Physalis,  Salpichroa,  Tubocapsicum,  Discopodium,
Treconaetes and Witheringia (18-21).
Cancer and its treatment
Cancer  is  a  group  of  heterogeneous  hyper
proliferative  disorder  that  causes  alterations  in
cellular signaling pathways leading to tumorogenesis
due to uninhibited proliferation and deregulation of
cell cycle and its apoptosis mechanisms (22). Various
hallmarks  of  cancer  are  transformation,  apoptotic
dysregulation,  proliferation,  invasion,  metastasis,
angiogenesis,  replicative  immortality  and  tumor
promoting  inflammations  (23).  Self-sufficiency  in
growth  signaling,  metastasis,  alteration  of  cellular
bioenergetics  and  invasion  of  immune  detaching
tissue, leading to alteration in apoptosis which causes
apoptosis  (24),  progression  of  this  tumor  is  due  to
gene instability and mutations (25). Across the world,
cancer  is  a  major  factor  contributing  to  increased
death rates. Cancers that show maximum death rates
are  colorectal,  stomach,  breast,  lung  and  prostate
cancer  (3).  Only  5% of  all  cancers  have  hereditary
causes;  while  the  rest  are due to either  internal  or
external environmental factors (10).
Based on the common hallmarks of cancer, most
treatment  techniques  selectively  interfere  with
replication of tumor and regulate homeostasis of the
cell  under  minimal  adversities.  Most  of  the
chemotherapeutic  agents  target  various  unique
cancer  hallmarks  in their  course of  treatment  (26).
Common cellular pathways that are targeted include
p53  signaling,  GM-CSF  signaling,  death  receptor
signaling,  apoptosis  signaling pathways respectively
and the G2-M DNA damage regulation pathway (27).
Common therapeutic approaches to treat cancer are
surgical  removal  of  tumor,  radiation  therapy,
chemotherapy and other specific targeted therapies.
Biotransformation of chemotherapeutic drugs in the
liver generates toxic and highly reactive metabolites
(28).  While  targeted  therapies  are  most  efficient  to
treat benign tumors with least noted side effects, they
are  difficult  to  treat  metastatic  cancers.  Various
plants  are  known  to  be  direct  sources  to  major
chemotherapeutic  drugs  against  cancer  worldwide.
Catharanthus roseus  is a source for vinblastine and
vincristine,  Podophyllum  spp.  are  source  for
podophyllotoxin  and  its  derivatives  etoposide  and
teniposide,  Taxus brevifolia  is a source for paclitaxel
(29).  While  many  plants  are  an  indirect  source  to
major  chemotherapeutic  drugs,  vinorelbine  and
doctaxel  are  semi  synthetic  derivative  of  Taxus
baccata;  irinotecan and topotecan are semi synthetic
derivatives of Camptotheca acuminata (30-32).
Major active compounds in anti-cancer activity
Studies show that withanolides obtained from roots
and  leaves  of  W.  somnifera  are  cytotoxic  to  tumor
cells  (33,  34)  and  possess  immunomodulatory  and
neuroprotective properties (1,  3, 35-41). In fact, most
withanolides inhibit various hallmarks of cancer and
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Fig. 2. Some important phytochemical constituents of Withania somnifera (L.) Dunal.
are  anti-proliferative,  anti-metastatic,  anti-
angiogenic, anti-invasive and pro-apoptotic (42). Most
of  these  phytochemicals  are  classified  under
chemotype  III  (43,  44).  Withanolides  are  also
biosynthesized  in  other  Withania  spp.  such  as  W.
aduensis, W. riebeckii  and W. coagulans (42); as well
as root and leaf extracts of non Withania spp. such as
Tubocapsicum  anomalum.  However,  only  2  species
that  show  economic  and  medicinal  significance  in
terms  of  amount  of  withanolide  synthesized,  its
composition,  ease  of  extraction  and  desired
bioactivity are W. somnifera and W. coagulans (41).
A  study  identified  inhibitory  concentration  in
µg/ml  of  a  mixture  of  withanolide-A  for  50%
reduction of lung, CNS, breast and colon cancer cells
as  0.24  ± 0.01  to  11.6  ±  1.9  respectively  for
withaferin A and its derivatives,  and 0.32  ± 0.05 to
0.47 ± 0.15 for visosalactone B and 7.9 ±  2.9 to 17.3 ±
3.9 for 27-O-glucoside derivative.  No inhibition was
seen in Physagulin D (45).
The  major  known  anti  tumorogenic  active
compound is a withanolide called withaferin-A (46).
Studies  have  demonstrated  various  mechanisms  of
anti-tumor  activity  by  withaferin-A  involving
activation  of  p53  and  ROS  signaling  (7,  34,  47),
increasing  intracellular  antioxidant  levels  (48),
induction of apoptosis (49-52), inhibition of activation
of NF-KappaB (53), inhibition of notch signaling (54,
55), cytoskeletal architecture alteration, angiogenesis
inhibition (56), down regulation of cyclin B1, cyclin A,
cdk2,  expression of  p-cdc2  and increase  in  cellular
levels of p-chk1 and p-chk2, all leading to cell cycle
arrest. Other mechanisms include down regulation of
oncoproteins,  p53  induction  and  accumulation,
increase in cellular levels of P-21, decrease in cellular
levels of STAT 3, increase in levels of  p53 mediated
apoptotic  markers  such  as  Bcl  2,  BAX,  caspase  3,
cleaved PARP and PAR 4, down-regulation of AKT and
EMT  signaling,  disruption  of  certain  cytoskeletal
elements  such  as  actin,  vimentin  and  intermediate
filaments (57-60), inhibition of cell proliferation and
alteration of cell differentiation (61), cell cycle arrest
(rarely at S phase and mostly at G2/M phase),  DNA
degradation  which  is  a  hall  mark  of  apoptosis,
inhibition  of  angiogenesis  and  metastasis  (62,  63).
Inhibition of external onco-proteins synthesis is also
seen  in  case  of  oncoproteins  E6  and  E7  of  human
papilloma  virus  predominantly  causing  cervical
cancer (64).
Mechanism of action against cancer 
A recent study demonstrates the detailed mechanism
of action of withaferin-A in prostate cancer cell lines
of  PC-3  and  DU-145.  Withaferin-A  arrests  the  cell
cycle of these tumorogenic cell lines at G2/M phase.
The mechanism for this arrest involves upregulation
of phosphorylated wee 1, phosphorylated histone H3,
P21  and  aurora  B,  with  a  simultaneous  down
regulation  of  cyclin  A2,  B1  and  E2,  and
phosphorylated  cdc  2  Tyr  (15).  As  a  result,  cellular
levels  of phosphorylated chk 1 (Ser 345)  and chk 2
(Thr 68) decrease.  This  leads to activation of cdc 2,
which  in  turn  facilitates  mitotic  catastrophe  in
abnormally duplicated cells by arresting its cycle at
M phase, ultimately causing death of the cell. 
General  studies  with  various  W.  somnifera
extracts  have  reported  their  ability  to  inhibit
enzymes  essential  for  the  cell’s  TCA  cycle  such  as
malate dehydrogenase and isocitrate dehydrogenase
in  test  animals  with  induced  colon  cancer  (65).
Myeloid  cells  are  known  to  regulate  tumor
progression. Myeloid derived suppressor cells (MDSC)
and tumor associated macrophages (TAM) are two of
the  most  common  tumor  regulating  myeloid  cells.
The growth of tumor is promoted by these MDSCs as
they  exhibit  inherent  immunosuppressive  abilities.
MDSCs  suppress  tumor  specific  T  lymphocytes  by
releasing T cell  suppressive reactive oxygen species
(ROS),  thereby  causing  immunosuppression  against
cancer  (66).  They  also  convert  macrophages  into  a
tumor  enhancing  phenotype  (67-70).  A  study
demonstrates  the  in  vitro ability  of  withaferin-A to
reduce the secretion of interleukin (IL) 6, TNP and α-
cytokines,  all  of  which  otherwise  increase  the
concentrations  of  MDSC.  As  a  result,  withaferin-A
successfully  reduces/inhibits  the  formation  of  these
reactive  oxygen  species  by  STAT  3  dependent
mechanism.  Hence,  a  tumor  rejecting  phenotype  is
achieved  by  reduction  of  myeloid  cell  immune
suppression  by  withaferin-A.  In  fact,  a  common
approach to immunotherapy of cancer involves the
antitumor  immune  response  activation.  In  most
cancer  patients,  withaferin-A  blocks  MDSC  and
inhibits metastasis of tumor, (71, 72); it also enhances
the  activation  of  tumor  reactive  cytotoxic  T
lymphocytes (73).
A  study  on  human  leukemia  cell  line  showed
that  mitochondrial  dependent  and  mitochondrial
independent apoptosis was induced by withaferin-A,
thus  leading  to  dysfunction  in  the  cell  and
subsequent restriction in growth of the tumor (74). A
crude  extract  of  W.  somnifera  has  the  ability  to
induce the hall mark of apoptosis in a cancer cell line
by  causing  its  DNA  fragmentation  (75).  Another
known  mechanism  of  cancer  proliferation  is  the
activity of telomerase; non-cancerous cells' life span
is  regulated  by  telomere  shortening.  Tumor  cells
overcome this mortality by activation of telomerase
which adds a sequence of TTAGGG at telomeric ends
thereby allowing the cells  to proliferate indefinitely
(76). Even cancerous cells that don’t contain telomere
have  shown  alternative  methods  to  increase  the
telomere  length.  Glioblastoma  multiforme,  gastric
carcinoma,  neuroblastoma,  liposarcoma,  epithelioid
sarcoma,  chondrosarcoma,  astrocytoma,  malignant
fibers  and  histiocytoma  are  some  of  the  common
tumors that have high prevalence of these alternate
telomere lengthening mechanisms (26, 77, 78). In the
absence  of  telomere  lengthening,  replicative
mortality is achieved by DNA damage signals which
lead to apoptosis.  Hence,  telomerase  inhibition is  a
potential cancer therapy.
Withaferin-A inhibits telomerase activity and the
subsequent  upregulation  of  DNA  damage  response
due to telomere dysfunction. Studies have also shown
that  the  activity  of  withaferin-A against  alternative
mechanisms  of  telomere  lengthening  is  even  more
efficient.  Withaferin-A  causes  transcriptional
suppression  of  an  MRN  complex  protein  NBS-1
mediated  by  myc-mad.  NBS-1  is  an  essential
component of alternative telomere lengthening (79).
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Conversion of  the  cellular  lipid  arachidonic  acid  to
prostaglandins which causes inflammatory response
is  carried  out  by  enzymes  cyclooxygenase  (COX)  1
and  2.  An  inflamed  or  cancerous  cell  has  high
expression  of  COX  2  (80-82).  An  effective  chemo-
preventive  approach  for  cancer  is  to  selectively
inhibit COX 2, which in turn inhibits COX 1 activity.
This  selective  inhibition of  COX 2 is  more effective
than  the  conventional  non-selective-non-steroidal-
anti-inflammatory  drugs  (83).  Studies  have  shown
that  W.  somnifera  leaf  extract  possesses  excellent
ability to selectively inhibit COX 2 (84).
The active compound triethylene glycol present
in  the  aqueous  extract  of  W.  somnifera  leaves  can
activate tumor suppressor genes like p53 and pRB. In
a  normal  cell,  there  is  an  increased  degree  of
phosphorylation  of  pRB  gene  which  increases  the
cellular concentration of cyclin B1; the latter in turn
decreases  the  concentration  of  cyclin  D1.  This
facilitates normal progression of the cell cycle. In a
cancerous  cell,  pRB  is  hypophosphorylated  which
decreases  the  cellular  concentration  of  cyclin  B1,
thereby increasing the concentration of cyclinD1; this
arrests  the  cell  cycle  and  cell  growth.  Triethylene
glycol also downregulates MMP 3 and MMP 9, which
are  metastasis  regulators  in  cancerous  cells,  while
normal cells remain unaffected (9).
Anti-tumorogenic activity of various extracts
Leaf extract
Studies  on  mice  assay  have  shown  that  the
methanolic  leaf  extract  of  W. somnifera  containing
withanolide-A,  withanoside  IV,  withaferin-A  and
withanoside  VI  is  non-toxic  and  anti-tumorogenic
predominantly  on  neuroblastoma.  The  cancer
inhibition factor of the leaf extract affects apoptosis
signaling, death receptor signaling, G2-M phase DNA
damage  regulation  pathway,  GM-CFS  signaling  and
most  commonly  p53 signaling.  The methanolic  and
chloroform  leaf  extract  containing  withaferin-A
causes nuclear translocation of p53. It also activates
p53 pathway and disrupts  cell  cycle in tumor cells.
Some studies have even claimed that p53 induced cell
cycle disruption can only be carried out by the leaf
extract and not the root extract of  W. somnifera  (7,
85).  A study on withaferin-A of the chloroform leaf
extract  reported that  it  arrests  cell  cycle  of  human
osteogenic sarcoma cell lines at G2, G1 and S phases
with  varying  cell  fractions.  Along  with  this  cancer
inhibition factor,  the hydroalcholic  leaf  extract also
contains polyphenolic compounds that are known to
control various cancer cell lines of the breast, ovary
and  lung  cancers  including  MCF-7,  A549  and  PA-1
(86).  The  aqueous  extract  of  W.  somnifera  leaves
activate  p53,  which  in  turn  increase  the
concentration of cyclin B1 (9). Another mechanism of
anti-cancer activity of the leaf extract is its ability to
selectively  inhibit  COX  2  enzyme activity  in  tumor
cells.
Root extract
W. somnifera chloroform root extracts have shown to
contain 1-oxo-5-β,6-β-epoxy witha-2-enolide and 5,6-
de-Epoxy-5-en-7-one-17-hydroxy  withaferin  A.
Studies have shown that this active compound down
regulates tumor in skin carcinoma cell line due to UV
exposure in rats;  other reports have shown activity
against  liver,  colon,  prostate  and  breast  cancer  as
well (87). The alcoholic  root extract has also shown
the  ability  to  inhibit  various  transcriptional  factors
such as NF-Kappa B and AP 1 (88). It can also induce
mitochondria-mediated  cytochrome  C  release  to
activate  caspases  for  apoptosis  of  cancer  cells  (89).
Studies  have  also  shown  the  ability  of  ethanolic,
chloroform and aqueous  root  extract  to  upregulate
Th1  dominant  polarization  which  causes  humoral
and  cell  mediated  immune  response  (39),  down
regulate  P34cdc2  expression  (90)  and  bring  about
nitric  oxide  synthase  induced  protein  expression,
NOS also produces nitric oxide which in turn causes
DNA damage and mutation by depurination and AT-
GC transition (91).
Fruit
The  fruits  of  W.  somnifera  contain  L-asparaginase
which  is  known  to  inhibit  the  growth  of
lymphoblastic  leukemia  (92).  A  study  involving  a
crude  aqueous  extract  of  the  fruit  assisted  by
potassium  chloride  and  ammonium  sulphate  from
which  L-asparaginase  was  isolated  by  various
chromatographic  columns  and  electrophoretic
techniques  was  found  to  be  cytotoxic  to  human
lymphoblastic  leukemia  cell  culture  at  various
inhibitory concentrations (93).
Anti-tumorogenic  activity  to  specific  cancer  cell
lines
Hepatocellular carcinoma
Hepatocellular carcinoma is the sixth most common
form of cancer and the second largest cause of cancer
related mortality in East Asia and Sub-Saharan Africa
(93),  and  hence  its  control  and  treatment  requires
great attention (94,  95).  Over 80% of hepatocellular
carcinoma cases are seen to occur in East Asia and
sub-Saharan  Africa  (96).  Hepatitis  C  virus  causes
cirrhosis  which  is  a  main  cause  of  hepatocellular
carcinoma.  The  major  risk  factors  of  human
hepatocellular  carcinoma  include  its  late  symptom
presentation,  aggressive  proliferation  and  poor
sensitivity  to  conventional  medication,  along  with
multiple  side  effects  (97,  98).  Common  treatment
strategies  of  hepatocellular  carcinoma  include
radiofrequency  ablation,  liver  transplantation,
transarterial chemoembolization, radioembolization,
curative resection and systemic targeted agents (99);
but toxicity, pain, fatigue, anemia, emotional distress
are  some  of  the  reported  side  effects  of  these
treatment  plans.  The  above  mentioned  treatments
are also expensive (100). Hence, various herbal plants
are used as complementary medicine to reduce the
tumor without  pain  (101).  Studies  have shown that
the use of methanolic and aqueous leaf extract of W.
somnifera  inhibits  hepatocellular  carcinoma  by
induction of apoptosis  and anti-oxidant  activities;  it
also employs other mechanisms for inhibition of cell
proliferation  and  alteration  in  cell  differentiation
(61).  The mechanism to restrict  tumor proliferation
in  hepatocellular  carcinoma  involves  withaferin-A
mediated  upregulation  of  Bim,  t-Bid  and caspase  8
(102), all of which cause inhibition of TNF α; this in
turn causes down regulation of cytokines and other
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proteins  involved  in  systematic  inflammation,  and
hence the inhibition of tumor (56). The aqueous leaf
extract  also  acts  against  Hep  G2  cell  line  of
hepatocellular  carcinoma  by  shrinking  and
decreasing the viability of the tumor (103). 
Skin cancer
Melanoma  is  the  most  aggressive  form  of  cancer
causing  over  75%  deaths  due  to  cancer  across  the
world.  Common chemotherapeutic  drugs  consumed
against  melanoma are  not  target  specific  and have
shown  various  side  effects.  Many  studies  on  W.
somnifera  alcoholic  (mostly  ethanolic  and
methanolic)  root  extract have proven it  as  a  target
specific treatment for melanoma with no side effects.
However, most of these studies have used melanoma
induced  mouse  as  a  target  and  very  few  are
conducted on human melanoma cell lines. It is also
seen  that  the  efficacy  of  this  root  extract  against
melanoma  cells  depends  on  dosage  and
treatment/incubation  time  (8).  Dimethyl
benzanthracene present in W. somnifera is known to
enhance  the  activity  of  antioxidant  enzymes  like
glutathione  peroxidase  and  catalase,  which  in  turn
reduce skin carcinogenesis (48). 
Breast cancer
Invasive breast cancer is one of the highest causes of
mortality  due  to  cancer.  There  have  been  over
232,340  cases  of  invasive  breast  cancer  and  64,640
cases  of  non-invasive  breast  cancer  of  all  breast
cancer cases in USA women in 2013. It has also been
predicted  that  African  American  women  are  more
likely to be affected by invasive breast cancer than
other American women. Tumor metastasis in lymph
nodes,  liver  and  lungs  is  the  main  cause  of  high
mortality in invasive breast cancer (104). 10 to 20% of
all  breast  cancer  cases  are  triple  negative  and
invasive;  it  is  resistant  to  most  conventional
chemotherapeutic drugs and radiation therapy. It is
also difficult  to treat due to its high metastasis  and
aggressive  proliferation.  W.  somnifera  extracts  can
treat this form of breast cancer effectively (105, 106).
A study conducted on nude mouse xenografts to treat
induced  breast  cancer  of  MDA-MB-231  cell  line,
showed  that  W.  somnifera  was  effective  in  the
treatment.  It  is  also known to  induce metastasis  in
MCF 7 and MDA 231 cell lines of human breast cancer
by inhibiting Notch signaling cascades. Withaferin-A
also  reduced  metastasis  in  triple  negative  invasive
breast cancer (26). 
Prostate cancer
Various  studies  and  surveys  have  claimed  that
prostate  cancer is  the third most common cause of
cancer  related  deaths  worldwide  and  second  most
common cause of cancer death in United States (107).
A  common  therapeutic  approach  to  reduce  the
proliferation  of  prostate  cancer  is  to  downregulate
androgen synthesis. Hence hormone ablation therapy
is  the  primary  treatment  for  prostate  cancer  (108).
Many  cases  of  castration  resistant  prostate  cancers
are  now  emerging  to  which  primary  treatment  is
ineffective  (109).  W.  somnifera  extracts  causes
downregulation of proinflammatory cytokines, which
in  turn  facilitates  the  upregulation  of  P38MAPK,
Caspase 6, Cyclin D1 and p13k, all of which inhibit the
growth  of  tumor  in  prostate  cancer.  Another
mechanism  specifically  to  prostate  cancers  of  PC-3
and DU-145 cell lines is the ability of withaferin-A to
regulate  G2/M phase  of  the  cell  cycle  and  stop  the
tumorous cell growth (64).
Lung cancer
Lung cancer is one of the leading causes of mortality
due to cancer worldwide with about 1 million deaths
per year (110). Conventional chemotherapeutic drugs
are often prescribed in any of these 3 combinations,
vinblastine  and  cisplatin  along  with  mitomycin;
cyclophosphamide,  doxorubicin  and  methotrexate,
procarbazine (111); or vincristine with cisplatin and
etoposide (112) or paclitaxel. Studies have shown that
withanolides suppress NF-KB and its regulated gene
products, which ultimately lead to anticancer activity
towards lung cancer cell line NCL-H460. Withaferin-
A, a chlorinated steroidal lactone 27-acetoxy-4β, 6α-
dihydroxy-5β-chloro-1-oxowitha-2,24-dienolide and a
diepoxywithanolide-5β, 6β, 14α, 15α, diepoxy 4β, 27-
dihydroxy-1-oxowith-2,24-dieolide,  extracted  from
the aerial parts of  W. somnifera have shown growth
inhibition towards lung cancer.  Withaferin-A is  the
most cytotoxic one of these three withanolides (113).
Colon and Colorectal cancer
Colorectal  cancer  is  common worldwide  (114),  and
the  fourth  leading  cause  of  deaths  due  to  cancer
across  the  world  (115).  A  common  treatment
approach  is  chemotherapy,  but  this  mode  of
treatment is not effective due to drug resistance in
tumor  cells,  as  well  as  high  toxicity  of  these
chemotherapeutic  drugs  towards  gastrointestinal
tract,  skin and bone marrow.  STAT 3 is  crucial  for
proliferation  of  colorectal  cancer  (116).  A  study
conducted on xenograft of nude mouse for colon and
colorectal  cancer  cell  line  HCT116  showed that  the
activation of STAT 3 signaling causes progression of
cell  cycle,  metastasis  and  angiogenesis,  thereby
increasing proliferation in the cell culture (117). STAT
3 inhibitions physiologically or chemotherapeutically
can cause prevention of colon cancer and promote its
apoptosis (118-120). Hence, a therapeutic alternative
is to directly inactivate STAT 3 (121). Withaferin-A is
seen to block interleukin 6 (IL 6), which induces STAT
3 activation, and thus cease the progression of colon
and  colorectal  cancer  tumor  proliferation. Other
mechanisms  by  which  W.  somnifera  inhibits  colon
and  colorectal  cancer  proliferation  include  the
generation  of  cytotoxic  reactive  oxygen  species,
inhibition  of  proteasome,  p53  stabilization,
endoplasmic reticulum stress induction, activation of
p38 MAPk, Akt phosphorylation inhibition, inhibition
of notch signaling cascades (122-124). 
Cervical cancer
Various  studies  have  shown that  a  major  cause  of
cervical  cancer  is  human  papilloma  virus  (HPV)
infestation  leading  to  over  70%  of  total  cervical
cancer cases worldwide.  HPV 16, 18,  31 and 33 are
mainly the causative  HPV for cervical cancer (125).
Tumor suppressor proteins, p53 and pRb which are
essential  for  cell  cycle  regulation and protection of
genome integrity (126) are inactivated by E6 and E7
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viral  oncoproteins  (127).  p53  and  p103-Rb  are
marked by E6 and E7 oncoproteins, but the resultant
mutation  is  reversible  (127).  Hence,  inhibition  of
these viral oncoproteins can reactivate p53 and lead
to apoptosis of cervical cancer cells (128-130). The cell
cycle  arrest  is  carried  out  by  transcriptional
activation  of  p21  cip1/waf1  which  is  a  cyclin
dependent kinase (131); this further activates Bax, a
proapoptotic  gene  product  (129,  130).  A  study
conducted  on  CaSKi  cell  line  of  human  cervical
cancer has found withaferin-A to possess the ability
to downregulate oncoproteins E6 and E7 expression
by HPV. This induces accumulation of p53 in tumor
cells  and  upregulation  of  p21  cip1/waf1,  which  in
turn interact with proliferating cell nuclear antigen
(PCNA),  leading  to  B1,  p34  cdc2  and  PCNA  levels-
modulated-G2/M-cell-cycle-arrest. Another  known
mechanism  of  cervical  cancer  inhibition  by
withaferin-A  includes  phosphorylation  of  Tyr-705
and Ser-727 and STAT 3, all of which lead to altered
expression of BCl 2, Bax, Caspase 2 and cleaved PARP,
which are p53 mediated apoptosis markers.
Ovarian cancer
Epithelial  ovarian  cancer  is  the  fifth  most  leading
cause of cancer deaths among American women (132,
133).  Common  therapeutic  measures  in  ovarian
cancer  patients  include  cyto-reductive  surgeries
followed  by  chemotherapy  using  carboplatin  by
platinum taxane, combined with paclitaxel. Although
in 70 to 80% of the cases, this treatment approach is
initially  effective,  in  over  70%  of  the  cases,  the
recurrent cancer developed due to cellular platinum
resistance leads to tumor relapse (134). Studies have
shown  that  this  chemo-resistance  is  due  to  cancer
stem cells (135) which are one of the major causes for
chemo resistance, tumor progression and relapse of
the cancer, post initial treatment (136, 137). The most
common  chemotherapeutic  drug  cisplatin  also
introduces  various  side  effects  including  nausea,
vomiting,  neurotoxicity,  severe  toxicity,
nephrotoxicity,  hepatotoxicity  and myelo-supression
(138-140).  The  mechanism  of  action  of  cisplatin
involves its  binding to the tumor cell  DNA forming
DNA adducts that lead to tumor suppression. A study
on  A2780  cell  line  of  human  orthotopic  ovarian
cancer  tested  on  mice  has  shown  a  reduction  of
tumor upto 70-80 % and total inhibition of metastasis
on  treatment  with  withaferin-A.  Withaferin-A  was
also  found to  target  cancer  stem cell  for  enhanced
anti  tumorogenic  activity  with  or  without  the
combination  of  cisplatin.  It  can  reduce  the  dosage
requirement  and  time  dependence  of  cisplatin  by
generating reactive oxygen species that lead to DNA
damage,  thereby  reducing  the  tumor  proliferation
(141,  142).  Hence,  a  combined  chemotherapeutic
treatment with cisplatin as well as withaferin-A can
enhance DNA damage.
Other  mechanisms  of  action  of  withaferin-A
against  ovarian  cancer  include  inactivation  of  Akt
and NF-kB leading to apoptosis,  induction of  Par 4,
activation of caspase 3 and caspase 9 which leads to
DNA  damage,  inhibition  of  HSP  90,  inhibition  of
FOXO  3a  and  Bim,  inhibition  of  Notch  1  and
downregulation  of  HPV  E6  and  E7  oncoprotein
expression.
W. somnifera as an adjuvant during radiation and
chemotherapy
W. somnifera  has shown the ability to proliferate or
normalize stem cells. A study on 75% methanolic  W.
somnifera extract revealed its ability to increase bone
marrow  cellularity,  reduce  γ  radiation  induced
leucopenia,  increase leukocyte count and normalize
normo-chromatic  erythrocytes  and  poly-chromatic
erythrocytes  ratio.  W.  somnifera  can  control  the
proliferation  of  tumor  and  hence  enhance  the
effectiveness  of  radiation  therapy  and  decrease  its
side effects (85).
Clinical  studies  on  anti-cancer  properties  of  W.
somnifera
There are very limited pre-clinical and clinical trials
conducted  on  herbal  extracts  for  their  claimed
medicinal  properties,  a major reason for this  is the
loopholes  in  guidelines  that  either  exempts  herbal
medicines from clinical  trials  or lacks strict  bylaws
(143). For the same reason, clinical studies are also
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very limited with respect to the anticancer aspects of
W.  somnifera and  its  phytochemical  constituents
(Table 1).
One  of  the  earliest  preclinical  trials  for
anticancer  property  of  withaferin-A was  conducted
on golden Syrian hamsters with oral cancer induced
by DMBA. Withaferin-A through oral intake of 20 mg
per kg of the host body mass for duration of 14 weeks
fully cured the cancer (144). A follow up study was
conducted  revealing  a  circadian  pattern  of
withaferin-A  activity  against  cancer.  It  was  found
that withaferin-A showed better anticancer property
on the host from 8 am to 12 pm with 100% protection
from tumor formation, whereas when the host was
treated at 12 am, it only served 50% protection from
tumor formation. The diurnal nature of antioxidant
enzymes activity and lipid peroxidation in the host
organism.  Studies  also  showed that  treatment  with
DMBA  and  withaferin-A  is  more  effective  in
reduction of protein expression of p53 and Bcl2 than
treatment with DMBA alone (145).
Another  study  was  conducted  on  mammary
carcinogenesis  developing in mmtvneu mice, which
was reduced by 33% with a treatment of 750 mg of
W. somnifera  root extract per kg for a period of 10
months  (146).  An  extended  study  used  the  same
model  but  the  dosage  was  changed  to  100  µg  per
mouse of withaferin-A alone, 3 times a week for 28
weeks and similar results were obtained with lower
metastasis of the lung and lower macroscopic tumor
weights  (147).  It  was  concluded  that  withaferin-A
inhibits  self-renewal  of  breast  cancer stem cells  by
altering  its  intermediary  metabolism  by  reducing
proteins  involved  in  TCA  and  glycolysis  (148).  The
tumor  stem  cell  machinery  is  also  obstructed  by
lowering  ALDH1  activity.  Further  studies  on
mammary cancer xenograft reveals that withaferin-A
has the ability to downregulate the cell proliferation
marker ki-67, surviving, XIAP and upregulate TUNEL
positive  apoptotic  cell  and  increase  the  protein
expression of pERK, pRSK, CHOP and DRS (149). 
A clinical study on DBA/2 female mice with skin
carcinogenesis  initiated  by  2  weeks  of  DMBA
application along with exposure to tumor promoter
12-o-tetradecanoyl phorbol-13-acetate was given a 20
µg dose of withaferin-A once a day, 5 times a week
for 14 weeks. Withaferin-A showed 100% efficacy of
tumor  prevention  by  blocking  the  upregulation  of
acetyl CoA carboxylase induced by the carcinogen. In
male  nude  mice  it  was  observed  that  4-8  µg  of
withaferin-A  per  kg  body  weight  daily  for  28  days
inhibited the tumor growth factor PC-3 and inhibited
the activity of proteosomal chymotrypsin (123). Some
studies injected withaferin-A into the host by patches
as well, a patch delivering 4 mg withaferin-A per kg
inhibited 60% of A549 lung cancer cases (150).
Clinical  studies  on human test  subjects  on this
regard  are  very  limited.  One  of  the  recent  studies
conducted  in  International  Institute  of  Herbal
Medicine  (IIHM),  Lucknow,  on  prostate  cancer,
dermatofibrosarcoma,  breast  cancer,  fibroids  of
uterus and squamous cell carcinoma of the penis in
last stages of the cancer without  conventional  drug
treatment  when modern treatment  was  refused by
the subjects, some of those were fully cured with W.
somnifera extract and radiologival intervention alone
(151). While side effects drastically reduced with the
use  of  this  extract  as  an  adjuvant  to  traditional
treatment in most of the other subjects (152).
Conclusion and Future perspectives
The  present  review  indicates  that  methanolic  and
aqueous  extracts  of  root  and stem of  W. somnifera
shows  anti-cancer  activity  by  either  induction  of
apoptosis,  cell  cycle  arrest  or  cytotoxicity  of  the
cancer  cells.  It  also  has  the  ability  to  control
progression  of  cancer  by  inhibition  metastasis  and
angiogenesis and can be used as an adjuvant during
radiation  and  chemotherapy.  The  prominent
mechanisms  for  its  activity  specifically  against
hepatocellular carcinoma, skin cancer, breast cancer,
prostate  cancer,  lung  cancer,  colon  and  colorectal
cancer,  cervical  cancer  and  ovarian  cancer  were
elaborated.  Some  of  these  mechanisms  are  Nitric
oxide synthase (NOS) upregulation and production of
reactive  oxygen species  (ROS)  leading  to  mutations
and DNA damage or mitochondrial dysfunction and
telomerase  inhibition  all  of  which  cause  apoptosis.
Inhibition  of  viral  oncoproteins  and other  immune
responses and activation of p53 and pRb leading to
cytotoxicity,  inhibition  of  angiogenesis  and
metastasis by MDSC and STAT 3 inhibition and VEGF
down  regulation  and  cell  cycle  arrest  caused  by
inhibition  of  transcription  factor  NF-kappaB.  Fig.  3
gives a diagrammatic representation of all the above
mentioned mechanisms of anti-cancer activity.
Although  biochemical  mechanisms  are
proposed, most of the studies are only held on animal
test  subjects.  Anti-tumorogenic  activity  of  W.
somnifera  is  yet  to  be  identified  for  various  newly
emerging  cancer  cell  lines.  Most  of  the  research
studies  referred  in  this  study  have  not  proposed a
definite  biochemical  mechanism  for  their  findings
yet. Anti-cancer activities against some cell lines have
only  been  proposed  based  on  molecular  docking
without consideration of any experiments involving
test subjects. Even the pre-clinical and clinical studies
conducted so far are mostly on animal test subjects.
Moreover, a large number of them use withaferin-A
as the therapeutic agent but not W. somnifera extract.
It is important to understand that the plant extract is
a  mixture  of  numerous  phytochemical  active
compounds in varying concentrations and testing the
viability  of  withaferin-A  alone  doesn’t  give  much
clarity  on  the  effect  of  the  whole  extract  which  is
mostly consumed in reality and as a result, test result
with  withaferin-A  must  be  extrapolated  for  the
extract.  Another  major  drawback of  the  previously
conducted  human  clinical  trials  includes
consideration of a small sample space which mostly
consists of older population.
Hence in the future, studies must be conducted
on human test subjects for the cell lines identified to
be affected by treatment with  W. somnifera extract.
Definite  mechanisms  must  also  be  proposed  for
cancer  cell  lines  regulated  by  W.  somnifera  yet
lacking a  biochemical  mechanism.  Effect  of  W.
somnifera treatment must be analyzed as a candidate
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phytotherapeutic  drug and a complete substitute  of
the  conventional  chemotherapeutic  drugs  against
various cancer cell lines.
Studies have also shown various adverse effects
on  human  consumption  of  W.  somnifera  including
fever,  rash,  diarrhea,  edema  and  abnormal  LFTs
(153).  Further  inspection  on  this  aspect  is  crucial,
research  must  also  be  undertaken  to  reduce  these
adverse effects. 
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